DexCom超出第四季度财报预期，投资者增持，分析师上调了价格目标。 DexCom beat Q4 earnings estimates, with investors increasing stakes and analysts raising price targets.

DexCom, Inc. (DXCM)报告,2026年2月12日,Q4收入强劲,有6.8 EPS和12.6亿美元的收入,比同年相比超过13.1%的估计数。 DexCom, Inc. (DXCM) reported strong Q4 earnings on February 12, 2026, with $0.68 EPS and $1.26 billion in revenue, surpassing estimates by 13.1% year-over-year. 机构投资者,包括Prosight Management LP、Ossiam、专题资产管理和Volterra Technologies LP,增加了对该公司的股份,该公司为糖尿病管理开发了持续的葡萄糖监测系统。 Institutional investors, including Prosight Management LP, Ossiam, Thematics Asset Management, and Volterra Technologies LP, increased their stakes in the company, which develops continuous glucose monitoring systems for diabetes management. 该股票在2026年3月初交易约64.24美元,市场上限为247.2亿美元,P/E比率为30.59。 The stock, trading around $64.24 in early March 2026, has a market cap of $24.72 billion and a P/E ratio of 30.59. 分析师维持“机动购买”共识评级,平均价格目标为85.50美元,得到高盛和威尔斯·法戈等公司的升级支持。 Analysts maintain a "Moderate Buy" consensus rating with an average price target of $85.50, supported by upgrades from firms like Goldman Sachs and Wells Fargo.